December 23, 2024

FDA Green-Lights Second GLP-1 Generic Drug

The FDA has approved the first generic GLP-1 injection for type 2 diabetes management, maintaining the safety profile and emphasizing clinical monitoring requirements for adverse effects.

Conexiant

December 20, 2024

POI Guidelines See First Major Update Since 2015

Four medical societies have revised their diagnostic criteria for premature ovarian insufficiency, now requiring only one elevated FSH test instead of two, while reporting a higher than previously known prevalence rate of 3.5% among women.

Conexiant

December 19, 2024

Plant-Based Meat Study Reveals Depression Link

A study on UK vegetarians and plant-based meat alternatives revealed surprising health outcomes related to depression, irritable bowel syndrome, and blood biochemistry levels.

Conexiant

December 19, 2024

FDA Redefines 'Healthy' Food Claims

The regulation requires qualifying foods to contain amounts from at least one food group or subgroup referenced in the Dietary Guidelines for Americans.

Conexiant

December 18, 2024

Understanding the 2022 WHO Classification of Endocrine Tumors

From the parathyroid to adrenal glands and thyroid tumors, the latest WHO classification introduces essential updates to tumor nomenclature and diagnostic criteria.

Conexiant

December 17, 2024

FDA Targets Unapproved GLP-1 Drug Sellers

The FDA has issued warning letters to companies for selling unapproved versions of popular diabetes and weight-loss drugs. The companies falsely labeled products for 'research use only' despite evidence showing they are intended for human use.

Reuters

December 16, 2024

New Drug Cuts Steroid Need in CAH

The FDA has approved crinecerfont (Crenessity) to manage androgen levels in classic congenital adrenal hyperplasia in individuals aged 4 or older. Find out more at FDA.

Conexiant

December 12, 2024

Brief, Vigorous Activity May Lower CV Risk in Women: Study Findings

A recent study shows that even 3.4 minutes of vigorous intermittent lifestyle physical activity per day could significantly reduce cardiovascular risk, particularly in non-exercising women.

Conexiant

December 12, 2024

Comparing Ticagrelor and Prasugrel in ACS

In a 17,642-patient cohort study validating ISAR-REACT5's findings, prasugrel showed particular benefit in STEMI patients, with a striking 38% relative risk reduction in adverse events compared to ticagrelor, while maintaining similar bleeding risks.

Conexiant